- In September 2019, Xeltis, a Swiss startup, has completed a USD 11.69 million Series D funding round to fund its valve and vascular research services. Established private and institutional investors, as well as all previous venture capitalists, contributed to the funding. Cardiovascular disease is the world's biggest cause of death. Through a therapy procedure known as ETR, Xeltis devices are designed to facilitate normal regeneration of the patient's blood vessels and hence cardiac function (Endogenous Tissue Restoration).
Frequently Asked Questions
The market is segmented based on Segmentation, By Technology (Cell Therapy, Stem Cell Therapy, Stem Cell Sources, Tissue Vascularization, Cell Culturing, Others), Raw Material (Synthetic, Genetically Modified, Biologic), Application (Cardiovascular, Oncology, Dermatology, Orthopedic, Neurology, Opthalmology, Others), End-User (Hospitals and Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Others) – Industry Trends and Forecast to 2032.
.
The North America Tissue Regeneration Market size was valued at USD 19.48 USD Billion in 2024.
The North America Tissue Regeneration Market is projected to grow at a CAGR of 14.5% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America.
